HC Wainwright reaffirmed their buy rating on shares of Indaptus Therapeutics (NASDAQ:INDP – Free Report) in a research note issued to investors on Monday, Benzinga reports. They currently have a $12.00 price target on the stock. HC Wainwright also issued estimates for Indaptus Therapeutics’ Q1 2024 earnings at ($0.57) EPS, Q2 2024 earnings at ($0.60) EPS, Q4 2024 earnings at ($0.34) EPS, FY2024 earnings at ($1.83) EPS, Q1 2025 earnings at ($0.38) EPS, Q2 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.35) EPS and FY2025 earnings at ($1.44) EPS.
Indaptus Therapeutics Trading Down 4.7 %
Shares of Indaptus Therapeutics stock opened at $2.66 on Monday. The firm has a market capitalization of $22.71 million, a PE ratio of -1.45 and a beta of 1.28. Indaptus Therapeutics has a 12 month low of $1.56 and a 12 month high of $4.08. The business’s 50-day moving average price is $2.13 and its 200-day moving average price is $2.10.
Indaptus Therapeutics (NASDAQ:INDP – Get Free Report) last issued its quarterly earnings results on Wednesday, March 13th. The company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.07. As a group, analysts predict that Indaptus Therapeutics will post -1.73 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
About Indaptus Therapeutics
Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.
Featured Articles
- Five stocks we like better than Indaptus Therapeutics
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- United Airlines Soars on Earnings Beat
- How to Evaluate a Stock Before Buying
- J.B. Hunt Hits the Skids: Lower Prices to Come
- How to buy stock: A step-by-step guide for beginners
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Indaptus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indaptus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.